CBP

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
Tuesday, April 9, 2024
Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 26, 2024
BRM, CBP, Foghorn, Webcast, SMARCA2, EP300, AACR, Conference, Conference call, Acute leukemia, Gene expression, AML, Pharmaceutical industry

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Key Points: 
  • Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
    Conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT
    CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT.
  • Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Mullen Automotive Provides Timeline Update on US Government Ruling for Class 1 EV Cargo Vans

Retrieved on: 
Wednesday, March 13, 2024
CBP, Mullen Technologies, EV, GSA, Government, IBN, RRDS, United States Customs Service

BREA, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc .

Key Points: 
  • BREA, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc .
  • (NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces an update on the U.S. Customs and Border Protection (“CBP”) application for Class 1 EV cargo vans.
  • Based on CBP advice, Mullen and RRDS are now proceeding with the GSA in order to finalize qualification of Mullen to sell Class 1 EV cargo vans to all branches of the U.S. government.
  • “Mullen is well positioned to support the U.S. government’s goal of transitioning its fleet to electric vehicles,” said David Michery, CEO and chairman of Mullen Automotive.

Transmute Executes Phase 5 Contract with US DHS S&T Silicon Valley Innovation Program

Retrieved on: 
Tuesday, March 19, 2024
Data Management, Technology, Transport, Security, Homeland Security, Software, Government Technology, Logistics, Supply Chain Management, Defense, Contracts, Public Policy, Government, United States Customs Service, S&T, DHS, Science, Digital, Silicon, Fraud, CBP, Data management, Red team, VDP, Cryptocurrency

Transmute , a leader in global trade digitalization, proudly announces the launch of their Phase 5 contract with the U.S. Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T) Silicon Valley Innovation Program (SVIP) .

Key Points: 
  • Transmute , a leader in global trade digitalization, proudly announces the launch of their Phase 5 contract with the U.S. Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T) Silicon Valley Innovation Program (SVIP) .
  • This data flow connects the fragmented and still majorly analog solutions that generate billions of paper documents annually.
  • The Phase 5 contract represents a significant advancement for Transmute, unlocking the ability to pursue direct contracts beyond CBP, with any of the 22 DHS agencies.
  • Karyl Fowler, CEO, says, "Transmute is proud to have reached this significant milestone with the U.S. Department of Homeland Security SVIP Team.

OSI Systems Supports U.S. Customs and Border Protection for Record Methamphetamine Seizure at a U.S. Port of Entry

Retrieved on: 
Tuesday, March 12, 2024
Other Defense, Contracts, Hardware, Law Enforcement, Emergency Services, Technology, White House, Federal Government, Immigration, Defense, Homeland Security, Government Technology, Other Technology, Military, Public Policy, Government, Narcotic, Camino Real International Bridge, AS&E, Methamphetamine, Seizure, Law enforcement, Aviation, Rapiscan Systems, Backscatter, Anomaly, OSI, CBP, OSI Systems, Drug

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that a non-intrusive inspection system from the Company’s Security division was used to detect six and a half tons of methamphetamine in a tractor-trailer truck at the Eagle Pass Port of Entry, the largest such seizure ever at a U.S. port of entry.

Key Points: 
  • OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that a non-intrusive inspection system from the Company’s Security division was used to detect six and a half tons of methamphetamine in a tractor-trailer truck at the Eagle Pass Port of Entry, the largest such seizure ever at a U.S. port of entry.
  • The scan revealed anomalies in the cargo and CBP officers subsequently discovered the narcotics, which had a street value of $117 million.
  • U.S. CBP has widely deployed Z Portal systems at various U.S. border ports of entry.
  • Rapiscan Systems and AS&E are subsidiaries of OSI Systems, Inc. and are leading global providers of security inspection solutions, equipment and services for aviation, ports, rail, customs and border protection, event security, critical infrastructure, public facilities, and law enforcement customers.

The CBSA and U.S. CBP provide an update on the NEXUS program

Retrieved on: 
Tuesday, April 2, 2024
Telephone, Transport, CBSA, Introduction, Interview, Crime, NEXUS, CBP, Airport, Canada Border Services Agency, Television

The current fee, set over 20 years ago, no longer covers the cost of the program.

Key Points: 
  • The current fee, set over 20 years ago, no longer covers the cost of the program.
  • The new fee would reflect more accurately the cost of administrating the program and the investment required for future program improvements, including technology and infrastructure enhancements.
  • The proposed increase would help keep up with the high demand for the program and continue to improve NEXUS.
  • The NEXUS program currently has over 1.8 million members, with the majority of members being Canadian.

Air Premia Joins TSA PreCheck® Program, Expediting Security Screening for U.S. Travelers

Retrieved on: 
Monday, April 1, 2024
Air Premia, Global Entry, Transport, KTN, Travel, Shoe, Moon, CBP, TSA PreCheck, Airport, TSA, Airline

The TSA PreCheck® program expedites the security screening process at participating U.S. airports.

Key Points: 
  • The TSA PreCheck® program expedites the security screening process at participating U.S. airports.
  • Eligible passengers enrolled in the TSA PreCheck program can enjoy the expedites security screening process at Air Premia's U.S. gateway city airports—Los Angeles, Newark, and San Francisco (launching May 17, 2024).
  • The TSA PreCheck program currently has more than 90 member airlines worldwide, and Air Premia is the third Korean national carrier to join.
  • By joining the TSA PreCheck program, we hope to further enhance our passengers' overall travel experience on Air Premia."

Biden Administration's Abuse of Parole for Illegal Aliens Now Outpaces Admission of Legal Immigrants, Finds New Report by FAIR

Retrieved on: 
Thursday, March 21, 2024
CAM, Congress, FY, El, Visa, Executive (government), Constitution, FAIR, CBP, Federation, Government, Legislation, Refugee, Drug

The Biden administration has paroled in at least 1.8 million individuals in two years, giving these illegal aliens nearly the same benefits as green card holders.

Key Points: 
  • The Biden administration has paroled in at least 1.8 million individuals in two years, giving these illegal aliens nearly the same benefits as green card holders.
  • This widespread abuse of parole authority has been carried out in order to make the unprecedented influx of illegal aliens under the Biden administration less visible to the American public.
  • "This week Congress is holding hearings to examine the scope and impact of the Biden administration's flagrant abuse of parole.
  • FAIR's full report, Immigration Parole: The Executive Branch's Shadow Immigration System, can be found here .

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2023 CHALLENGE AWARDS TOTALING MORE THAN $21 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Thursday, March 14, 2024
University of Illinois Urbana-Champaign, PCF, University of Sydney, Prostate cancer, Genetic testing, Immunotherapy, Prostate Cancer Foundation, Lund University, Oncogene, Patient, PET, Biomarker, Research, Aircraft pilot, University, Doctor of Philosophy, Biology, MBA, MPH, Johns Hopkins University, Institute of Cancer Research, CBP, University of Pretoria, PSMA, Medical imaging

LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 20 highly coveted PCF Challenge Awards totaling $21.3 million were granted to teams at some of the world's leading cancer research institutions.
  • (Evaluating the impact of treatment with darolutamide on age-related outcomes in vulnerable, older patients with metastatic hormone-sensitive prostate cancer.)

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
Thursday, March 7, 2024
EP300, NSCLC, Merck, Research, AML, Neoplasm, ARID1B, Investment, CBP, Cancer, Prostate, AACR, Factorization of polynomials, Lung cancer, Safety, MDS, Collaboration, Gene expression, Thrombocytopenia, Lilly, Medicine, Patient, Survival, IND, LDAC, Development, Colorectal cancer, BRM, Chromatin, Prostate cancer, Pharmaceutical industry

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.